Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 51 of 67 for:    "Acute Lymphocytic Leukemia" | "Hydrocortisone"

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03792256
Recruitment Status : Recruiting
First Posted : January 3, 2019
Last Update Posted : October 31, 2019
Sponsor:
Information provided by (Responsible Party):
Children's Oncology Group

Brief Summary:
AINV18P1 is a Phase 1 study where palbociclib will be administrated in combination with a standard re-induction platform in pediatric relapsed Acute Lymphoblastic Leukemia (ALL) and lymphoblastic lymphoma (LL). LL patients are included because the patient population is rare and these patients are most commonly treated with ALL regimens. The proposed starting dose for this study will be 50 mg/m^2/day for 21 days.

Condition or disease Intervention/treatment Phase
Leukemia, Lymphocytic Lymphoblastic Lymphoma T-cell Lymphoma T-cell Leukemia Recurrent Disease Acute Leukemia Drug: Palbociclib Drug: Cytarabine Drug: Methotrexate Drug: Hydrocortisone Drug: Doxorubicin Drug: Prednisolone Drug: Vincristine Drug: Pegaspargase Phase 1

Detailed Description:

PRIMARY OBJECTIVES:

I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of palbociclib administered in combination with re-induction chemotherapy in pediatric patients with relapsed B- or T-lineage ALL/LL.

II. To define and describe the toxicities of palbociclib administered on this schedule.

III. To characterize the pharmacokinetics of palbociclib in pediatric patients with relapsed B- or T-lineage ALL/LL.

SECONDARY OBJECTIVES:

I. To preliminarily define the antitumor activity of palbociclib in combination with chemotherapy for children with relapsed ALL/LL within the confines of a Phase 1 study.

II. To assess the biologic activity of palbociclib in this patient population.

OUTLINE:

Patients receive Palbociclib PO (or via NG- tube) once daily on Days 1-21; Intrathecal cytarabine (IT ARAC) on Day 1, Doxorubicin IV push or infusion over 1-15 min on Day 4; Prednisone or prednisolone PO on days 4-31; Vincristine IV push or mini-bag per institutional policy on days 4, 11, 18, and 25; and Pegaspargase IV over 1-2 hours on Days 5, and 18. If CNS3 leukemia is present, patients receive Intrathecal Triple Therapy (ITT) on days 4, 11, 18, and 25. If CNS1 and 2 leukemia present, patient receive Methotrexate (IT MTX) on Days 18 and 32. Treatment will be given for one cycle, 32 days, in the absence of disease progression or unacceptable toxicity.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study Of Palbociclib (IND#141416), A CDK 4/6 Inhibitor, In Combination With Chemotherapy In Children With Relapsed Acute Lymphoblastic Leukemia (ALL) Or Lymphoblastic Lymphoma (LL)
Actual Study Start Date : April 11, 2019
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : September 30, 2020


Arm Intervention/treatment
Experimental: Treatment (Palbociclib)
Patients receive Palbociclib 50 mg/m^2 (starting dose with maximum dose of 100 mg) PO (or via NG- tube) once daily on Days 1-21; Intrathecal cytarabine (IT ARAC) age-based dosing on Day 1, Doxorubicin 60 mg/m^2 IV push or infusion over 1-15 min on Day 4; Prednisone or prednisolone 40 mg/m^2 PO divided BID or TID on days 4-31; Vincristine 1.5 mg/m^2 (maximum dose 2 mg) IV push or mini-bag per institutional policy on days 4, 11, 18, and 25; and Pegaspargase 2500 IU/m^2 IV over 1-2 hours on Days 5, and 18. If CNS3 leukemia is present, patients receive Intrathecal Triple Therapy (ITT) age-based dosing on days 4, 11, 18, and 25. If CNS1 and 2 leukemia present, patient receive Methotrexate (IT MTX) age-based dosing on Days 18 and 32. Treatment will be given for one cycle, 32 days, in the absence of disease progression or unacceptable toxicity.
Drug: Palbociclib
Given PO (or via NG- tube)

Drug: Cytarabine
Given IT

Drug: Methotrexate
Given IT

Drug: Hydrocortisone
Given IT

Drug: Doxorubicin
Given IV

Drug: Prednisolone
Given PO

Drug: Vincristine
Given IV

Drug: Pegaspargase
Given IV




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) of Palbociclib [ Time Frame: Up to 32 days ]
    MTD will be the maximum dose at which fewer than one-third of patients experience dose limiting toxicities.

  2. Incidence of adverse events [ Time Frame: Up to 4 years ]
    Will be graded using the Common Terminology Criteria for Adverse Events version 4.0

  3. Pharmacokinetics of palbociclib: Time to maximum plasma concentration (Tmax) [ Time Frame: Pre-dose, and at 1, 2, 4, 8 and 24 hours post-dose of palbociclib on Days 1 and 11 ]
    Palbociclib plasma concentrations will be measured after single agent administration as well as when combined with chemotherapy at a centralized laboratory using a validated liquid chromatography/tandem mass spectrometry assay. PK parameters (Tmax, Cmax, t1/2, AUC, Cl/F) of palbociclib will be calculated using standard non-compartmental or compartmental methods and summarized with descriptive summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).

  4. Pharmacokinetics of palbociclib: Maximum plasma concentration (Cmax) [ Time Frame: Pre-dose, and at 1, 2, 4, 8 and 24 hours post-dose of palbociclib on Days 1 and 11 ]
    Palbociclib plasma concentrations will be measured after single agent administration as well as when combined with chemotherapy at a centralized laboratory using a validated liquid chromatography/tandem mass spectrometry assay. PK parameters (Tmax, Cmax, t1/2, AUC, Cl/F) of palbociclib will be calculated using standard non-compartmental or compartmental methods and summarized with descriptive summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).

  5. Pharmacokinetics of palbociclib: Terminal phase half-life (t1/2) [ Time Frame: Pre-dose, and at 1, 2, 4, 8 and 24 hours post-dose of palbociclib on Days 1 and 11 ]
    Palbociclib plasma concentrations will be measured after single agent administration as well as when combined with chemotherapy at a centralized laboratory using a validated liquid chromatography/tandem mass spectrometry assay. PK parameters (Tmax, Cmax, t1/2, AUC, Cl/F) of palbociclib will be calculated using standard non-compartmental or compartmental methods and summarized with descriptive summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).

  6. Pharmacokinetics of palbociclib: Area under the plasma concentration (AUC) [ Time Frame: Pre-dose, and at 1, 2, 4, 8 and 24 hours post-dose of palbociclib on Days 1 and 11 ]
    Palbociclib plasma concentrations will be measured after single agent administration as well as when combined with chemotherapy at a centralized laboratory using a validated liquid chromatography/tandem mass spectrometry assay. PK parameters (Tmax, Cmax, t1/2, AUC, Cl/F) of palbociclib will be calculated using standard non-compartmental or compartmental methods and summarized with descriptive summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).

  7. Pharmacokinetics of palbociclib: Plasma Clearance (CI/F) [ Time Frame: Pre-dose, and at 1, 2, 4, 8 and 24 hours post-dose of palbociclib on Days 1 and 11 ]
    Palbociclib plasma concentrations will be measured after single agent administration as well as when combined with chemotherapy at a centralized laboratory using a validated liquid chromatography/tandem mass spectrometry assay. PK parameters (Tmax, Cmax, t1/2, AUC, Cl/F) of palbociclib will be calculated using standard non-compartmental or compartmental methods and summarized with descriptive summary statistics, including means, medians, ranges, and standard deviations (if numbers and distribution permit).


Secondary Outcome Measures :
  1. Antitumor activity of palbociclib as assessed by response rates at the end of the treatment cycle. [ Time Frame: Day 32 ]
    A bone marrow aspirate will be performed on Day 32 in patients with ALL and morphological bone marrow blast percentage will be determined. The clinical response of any extramedullary disease sites will also be assessed. The blast percentage in the bone marrow in conjunction with the clinical response in any involved extramedullary disease sites will be used to determine the overall response designation at the end of the treatment cycle in patients with ALL.

  2. Antitumor activity of palbociclib as assessed by absolute peripheral blast count. [ Time Frame: Baseline and after 72 hours ]
    As an early measure of response to single agent palbociclib, the absolute peripheral blast count will be measured at baseline and after 72 hours of drug exposure in patients with ALL and peripheral blood circulating blasts >1000/mm^3.

  3. Antitumor activity of palbociclib as assessed by response rates at the end of the treatment cycle. [ Time Frame: Day 32 ]
    Imaging studies will be performed on Day 32 in patients with LL. Morphological evaluation of the bone marrow (if involved at diagnosis) will also be performed on Day 32 in patients with LL. Disease response will be determined using the new International Pediatric Non-Hodgkin Lymphoma Response Criteria and the major response designations will be established by CT or MRI of involved sites in conjunction with morphologic evaluation of bone marrow (BM) if involved at diagnosis.

  4. Biologic activity of palbociclib will be assessed with assays measuring cell cycle inhibition. [ Time Frame: Day 4 ]
    Bone marrow (or peripheral blood if the absolute blast count is >1000/mm3) samples will be collected pre-study and on Day 4 after 72 hours of single agent palbociclib exposure. Participation in these studies is optional. Expression of RB1, phospho-RB1, Cyclin D3, CDK4, CDK6 and p27Kip1 will be performed using Western Blotting (immunoblotting).

  5. Biologic activity of palbociclib will be assessed with assays measuring cell cycle inhibition. [ Time Frame: Day 32 ]
    Cell cycle analyses will also be performed before and after drug exposure using standard flow cytometry methods combining surface staining for ALL markers (e.g., CD1a, CD3, CD4, CD8) and intracellular staining for the cell cycle (and apoptosis) markers Ki67 and DAPI. These assays will also be performed at the end of the treatment cycle in residual blasts in those patients who have failed to achieve remission.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Months to 31 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with recurrent or refractory B- or T-lineage lymphoblastic leukemia and lymphoma.
  • Patients with leukemia must have ≥ 5% (M2 or M3) bone marrow blasts with or without an extramedullary site of relapse. Morphologic relapse for M2 should be confirmed using flow cytometry, FISH and/or cytogenetics or molecular techniques.
  • Patients with LL must have either measurable or evaluable disease.
  • Patients with first or greater relapsed T-lineage ALL or LL and second or greater relapsed B-lineage ALL or LL are eligible.
  • Patients with primary refractory disease with at least 2 prior induction attempts or first relapse refractory to at least one prior re-induction attempt are eligible.
  • Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients <= 16 years of age.

    • Note: Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the numerical eligibility criteria are met, e.g., blood count criteria, the patient is considered to have recovered adequately.

    1. Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive. See DVL homepage for commercial and Phase 1 investigational agent classifications. For agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned Research Coordinator prior to enrollment.

      • A waiting period prior to enrollment is not required for patients receiving standard cytotoxic maintenance chemotherapy (i.e., corticosteroid, vincristine, 6MP, and/or methotrexate).
      • Intrathecal cytotoxic therapy: No waiting period is required for patients having received intrathecal cytarabine, methotrexate, and/or hydrocortisone. Intrathecal chemotherapy given at the time of diagnostic LP to evaluate for relapse prior to study enrollment is allowed.

        • 14 days must have elapsed after the completion of other cytotoxic therapy, with the exception of hydroxyurea, for patients not receiving standard maintenance therapy. Additionally, patients must have fully recovered from all acute toxic effects of prior therapy.

          • NOTE: Cytoreduction with hydroxyurea in patients can be initiated and continued for up to 24 hours prior to the start of protocol therapy.
          • Note: Intrathecal chemotherapy that is given up to 72 hours prior to initiation of systemic chemotherapy per AINV18P1 counts as protocol therapy and not prior anti-cancer therapy. Intrathecal chemotherapy given > 72 hours prior does not count as protocol therapy.
    2. Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or ANC counts): >= 7 days after the last dose of agent. See DVL homepage for commercial and Phase 1 investigational agent classifications. For agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned Research Coordinator prior to enrollment.

      • NOTE: Cytoreduction with prednisone or methylprednisolone for <= 120 hours (5 days) in patients can be initiated and continued for up to 24 hours prior to the start of protocol therapy.
    3. Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody with the exception of blinatumomab, and toxicity related to prior antibody therapy must be recovered to Grade <= 1. Patients must have been off blinatumomab infusion for at least 14 days and all drug related toxicity must have resolved to Grade <= 1.
    4. Corticosteroids: If used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid and toxicity related to prior immune therapy must be recovered to Grade <= 1 off corticosteroids.
    5. Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair and the study-assigned Research Coordinator.
    6. Interleukins, Interferons and Cytokines (other than Hematopoietic Growth Factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than Hematopoietic Growth Factors)
    7. Stem cell Infusions (with or without TBI):

      • Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including DLI or boost infusion: >= 84 days after infusion and no evidence of GVHD.
      • Autologous stem cell infusion including boost infusion: >= 42 days.
    8. Cellular Therapy: >= 30 days after the completion of any type of cellular therapy (e.g. modified T cells, NK cells, dendritic cells, etc.)
    9. XRT/External Beam Irradiation including Protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial BM radiation.
    10. Patients must not have received prior exposure to palbociclib or another CDK4/6 inhibitor.
  • Adequate Renal Function Defined as:

    • Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or
    • A serum creatinine based on age/gender as follows:

      • Age: 1 to < 2 years; Male: 0.6 mg/dL; Female: 0.6 mg/dL
      • Age: 2 to < 6 years; Male: 0.8 mg/dL; Female: 0.8 mg/dL
      • Age: 6 to < 10 years; Male: 1 mg/dL; Female: 1 mg/dL
      • Age: 10 to < 13 years; Male: 1.2 mg/dL; Female: 1.2 mg/dL
      • Age: 13 to < 16 years; Male: 1.5 mg/dL; Female: 1.4 mg/dL
      • Age: >= 16 years; Male: 1.7 mg/dL; Female: 1.4 mg/dL
  • Adequate Liver Function Defined as:

    • bilirubin (sum of conjugated + unconjugated) <= 1.5 x upper limit of normal (ULN) for age
    • SGPT (ALT) <= 225 U/L unless disease-related. For the purpose of this study, the ULN for SGPT is 45 U/L.
    • Serum albumin >= 2 g/dL.
  • Adequate Cardiac Function Defined As:

    • Shortening fraction of >= 27% by echocardiogram, or
    • Ejection fraction of >= 50% by gated radionuclide study.
  • All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines.

Exclusion Criteria:

  • Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Based on the mechanism of action, palbociclib may be expected to cause fetal harm if used during pregnancy. Pregnancy tests must be obtained in girls who are post-menarche. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study therapy. Women of reproductive potential should use effective contraception during treatment and for at least 3 weeks after the last dose of palbociclib. Males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last dose of palbociclib. Animal data suggests that palbociclib may affect male fertility.
  • Prednisone or methylprednisolone for ≤ 120 hours (5 days) may be administered for cytoreduction up to 24 hours prior to the start of protocol therapy and as treatment for allergic reactions or for physiologic replacement/stress dosing of hydrocortisone for documented adrenal insufficiency. Corticosteroids are not allowed for other indications. If used to modify immune adverse events related to prior therapy, ≥ 14 days must have elapsed since last dose of corticosteroid.
  • Patients who are currently receiving another investigational drug.
  • Patients who are currently receiving other anti-cancer agents are not eligible [except patients receiving hydroxyurea, which may be continued until 24 hours prior to start of protocol therapy].
  • Patients who are currently receiving drugs that are strong inhibitors and/or inducers of CYP3A4 or sensitive CYP3A4 substrates and CYP3A4 substrates with a narrow therapeutic range are not eligible. Strong inducers or inhibitors of CYP3A4 are prohibited from 14 days prior to enrollment to the end of the study.
  • Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant.
  • Patients must be able to swallow intact capsules or liquid. Patients that are unable to swallow oral medications may receive palbociclib through an NG tube. G tube administration is not allowed.
  • Patients who have an uncontrolled infection defined as below:

    • Fever above 38.2°C within 48 hours of study enrollment with clinical signs of infection. Fever that is determined to be due to tumor burden is allowed if patients have documented negative blood cultures for at least 48 hours prior to enrollment and no concurrent signs or symptoms of active infection or hemodynamic instability.
    • A positive fungal culture within 30 days of study enrollment or active therapy for presumed invasive fungal infection.
    • Patients may be receiving IV or oral antibiotics to complete a course of therapy for a prior documented infection as long as cultures have been negative for at least 48 hours and signs or symptoms of active infection have resolved. For patients with c. difficile diarrhea, at least 72 hours of antibacterial therapy must have elapsed and stools must have normalized to baseline.
    • Active viral or protozoal infection requiring IV treatment.
  • Patients known to have one of the following concomitant genetic syndromes: Down syndrome, Bloom syndrome, ataxia-telangiectasia, Fanconi anemia, Kostmann syndrome, Shwachmann syndrome or any other known bone marrow failure syndrome.
  • Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03792256


Locations
Layout table for location information
United States, Alabama
Children's Hospital of Alabama Recruiting
Birmingham, Alabama, United States, 35233
Contact: Gregory K. Friedman, MD    205-939-9285    gfriedman@peds.uab.edu   
Principal Investigator: Matthew A. Kutney, MD         
United States, California
Loma Linda University Medical Center Recruiting
Loma Linda, California, United States, 92354
Contact: Albert Kheradpour, MD    909-558-4076    AKheradp@llu.edu   
Principal Investigator: Albert Kheradpour, MD         
Children's Hospital of Orange County Recruiting
Orange, California, United States, 92868
Contact: Josephine H. Haduong, MD    714-997-3000    jhaduong@choc.org   
Principal Investigator: Elyssa M. Rubin, MD         
Lucile Packard Children's Hospital Stanford University Recruiting
Palo Alto, California, United States, 94304
Contact: Jay Michael S. Balagtas, MD    650-723-5535    balagtas@stanford.edu   
Principal Investigator: Jay Michael S. Balagtas, MD         
United States, District of Columbia
Children's National Medical Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: AeRang S. Kim, MD    202-884-2549    aekim@childrensnational.org   
Principal Investigator: Jeffrey S. Dome, MD, PhD         
United States, Georgia
Children's Healthcare of Atlanta - Egleston Recruiting
Atlanta, Georgia, United States, 30322
Contact: Jason R. Fangusaro, MD    888-785-1112    jfangus@emory.edu   
Principal Investigator: William T. Cash, MD,MSc         
United States, Indiana
Riley Hospital for Children Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Melissa K. Bear, MD    317-274-8784    memarkel@iupui.edu   
Principal Investigator: Sandeep Batra, MD         
United States, Michigan
C S Mott Children's Hospital Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Rajen Mody, MD    877-475-6688    rmody@med.umich.edu   
Principal Investigator: Rajen Mody, MD         
United States, Minnesota
University of Minnesota/Masonic Cancer Center Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Joseph P. Neglia    612-624-2620    jneglia@umn.edu   
Principal Investigator: Joseph P. Neglia, MD, MPH         
University of Minnesota/Masonic Cancer Center Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Emily P. Greengard, MD    612-624-2620    emilyg@umn.edu   
Principal Investigator: Joseph P. Neglia         
United States, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone Recruiting
New York, New York, United States, 10016
Contact: Elizabeth A. Raetz    212-263-4434    prmc.coordinator@nyumc.org   
Principal Investigator: Elizabeth A. Raetz         
Laura and Isaac Perlmutter Cancer Center at NYU Langone Recruiting
New York, New York, United States, 10016
Contact: Sharon L. Gardner, MD    212-263-4434    prmc.coordinator@nyumc.org   
Principal Investigator: Sharon L. Gardner, MD         
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center Recruiting
New York, New York, United States, 10032
Contact: Alice Lee, MD    212-305-5808    al2041@cumc.columbia.edu   
Principal Investigator: Alice Lee, MD         
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Joseph G. Pressey, MD    513-636-4266    joseph.pressey@cchmc.org   
Principal Investigator: John P. Perentesis, MD         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Rene Y. McNall-Knapp    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: Rene Y. McNall-Knapp         
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Rene Y. McNall-Knapp    405-271-4272    julie-traylor@ouhsc.edu   
Principal Investigator: Rene Y. McNall-Knapp         
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Elizabeth Fox, MD    267-426-0948    foxe@email.chop.edu   
Principal Investigator: Frank M. Balis, MD         
Children's Hospital of Pittsburgh of UPMC Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: Jean Tersak, MD    412-692-5055    Jean.Tersak@chp.edu   
Principal Investigator: Jean M. Tersak, MD         
United States, Tennessee
Saint Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: Wayne Furman, MD    901-595-3300    wayne.furman@stjude.org   
Principal Investigator: Wayne Furman, MD         
United States, Utah
Primary Children's Hospital Recruiting
Salt Lake City, Utah, United States, 84113
Contact: Phillip E. Barnette, MD    801-662-4700    phillip.barnette@imail.org   
Principal Investigator: Phillip E. Barnette, MD         
United States, Washington
Seattle Children's Hospital Recruiting
Seattle, Washington, United States, 98105
Contact: Julie R. Park, MD    206-987-2106    julie.park@seattlechildrens.org   
Principal Investigator: Douglas S. Hawkins, MD         
Sponsors and Collaborators
Children's Oncology Group
Investigators
Layout table for investigator information
Study Chair: Elizabeth Raetz, MD Children's Oncology Group

Layout table for additonal information
Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT03792256     History of Changes
Other Study ID Numbers: AINV18P1
First Posted: January 3, 2019    Key Record Dates
Last Update Posted: October 31, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hydrocortisone
Lymphoma
Leukemia
Leukemia, Lymphoid
Lymphoma, Non-Hodgkin
Leukemia, T-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Cytarabine
Prednisolone
Methylprednisolone Acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone acetate
Doxorubicin
Liposomal doxorubicin
Methotrexate
Vincristine
Palbociclib
Pegaspargase
Prednisolone hemisuccinate
Prednisolone phosphate
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors